SCHEMBL18173533

SCHEMBL18173533

CCOC(C(=O)c1ccc(-c2cc(OC)c(Cl)c(OC)c2)o1)c1ccc(-c2nnc(CO)s2)cc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 3/20 0.81
PDE2A O00408 1/20 0.81
PDE5A O76074 1/20 0.81
ALDH1A1 P00352 7/20 0.36
KDM4E B2RXH2 7/20 0.36
HPGD P15428 4/20 0.36
MAPT P10636 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
HSD17B10 Q99714 3/20 0.36
QPCTL Q9NXS2 1/20 0.33
POLB P06746 1/20 0.33
ALOX15 P16050 1/20 0.33
LMNA P02545 2/20 0.33
GUSB P08236 1/20 0.33
ALOX5 P09917 1/20 0.32
PTGS1 P23219 1/20 0.32
PTGS2 P35354 1/20 0.32
OGA O60502 1/20 0.32
RAB9A P51151 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18412709 0.92 PDE10A (0.71) PDE10APDE2APDE5AALDH1A1KDM4E
SCHEMBL17223619 0.90 PDE10A (1.00) PDE10APDE2APDE5AALDH1A1KDM4E
SCHEMBL17236186 0.90 PDE10A (1.00) PDE10APDE2APDE5AALDH1A1KDM4E
SCHEMBL2388915 0.90 PDE10A (1.00) PDE10APDE2APDE5AALDH1A1KDM4E
SCHEMBL18173549 0.85 PDE10A (0.90) PDE10APDE2APDE5AALDH1A1KDM4E
SCHEMBL18173544 0.84 PDE10A (0.89) PDE10APDE2APDE5AALDH1A1KDM4E
SCHEMBL18177059 0.82 PDE10A (0.65) PDE10APDE2APDE5AALDH1A1KDM4E
SCHEMBL2388041 0.82 PDE10A (0.75) PDE10APDE2APDE5AALDH1A1KDM4E
SCHEMBL17471106 0.82 PDE10A (0.86) PDE10APDE2APDE5AALDH1A1KDM4E
SCHEMBL17464697 0.82 PDE10A (0.86) PDE10APDE2APDE5AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3285760-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS Omeros Corporation (US) 2018-02-28 EP disclosed
US-9879002-B2 PDE10 inhibitors and related compositions and methods OMEROS CORPORATION (US) 2018-01-30 US disclosed
US-9879002-B2 PDE10 inhibitors and related compositions and methods OMEROS CORPORATION (US) 2018-01-30 US disclosed
US-9879002-B2 PDE10 inhibitors and related compositions and methods OMEROS CORPORATION (US) 2018-01-30 US disclosed
US-20170022190-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION 2017-01-26 US disclosed
US-20170022190-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION 2017-01-26 US disclosed
WO-2016172573-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION (US) 2016-10-27 WO disclosed
WO-2016172573-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION (US) 2016-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170022190-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS PDE10A, PDE9A, PDE7A PDE10A 1/4885PDE2A 9/4885PDE5A 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.